Article

Phase III trials begin for steroid compound

Tampa-Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery.

Tampa-Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery.

Sirion acquired the drug last year through an exclusive licensing agreement with Senju Pharmaceutical Co. Ltd., Japan. The deal gave Sirion U.S. rights to develop and market a topical ophthalmic emulsion containing difluprednate for the treatment of inflammatory eye diseases.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
© 2025 MJH Life Sciences

All rights reserved.